TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31402223
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL 0.25% plain bupivacaine (100 mg)
Study: 24799482
Drug: PET-negative residues
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-negative residues after chemotherapy (548 patients)
Study: 22443921
Drug: Manual compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual compression with hemostatic patch
Study: 22443921
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (manual compression with and without hemostatic patch)
Study: 20185734
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (OI) - 300 units combined with 400 mg of delivery agent orally
Study: 20185734
Drug: Subcutaneous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous regular human insulin (RHI) - 15 units
Study: 18602250
Drug: Daily supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplements containing 60 mg of iron and 250 microg of folic acid plus 25 mg of zinc
Study: 18602250
Drug: Daily supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplements containing 60 mg of iron and 250 microg of folic acid
Study: 11465711
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (specific treatments not detailed)
Study: 8158065
Drug: Saphenous patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saphenous patch (Group B)
Study: 8158065
Drug: Prosthetic Gore-Tex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosthetic Gore-Tex patch (Group C)
Study: 2895124
Drug: Residual antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual antibacterial activity with chlorhexidine gel
Study: 26073754
Drug: HDM extract
Normalized name: American house dust mite allergenic extract 6 SQ-HDM / European house dust mite allergenic extract 6 SQ-HDM [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM extract (active) administered orally twice daily for 12 months
Study: 26073754
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution administered orally twice daily for 12 months
Study: 19590194
Drug: Amitriptyline 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 37.5 mg twice daily for 14 days (pilot study)
Study: 19590194
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg once daily for 28 days (phase II study)
Study: 19590194
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg once daily for 28 days (phase II study)
Study: 19590194
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg once daily for 28 days (phase II study)
Study: 15253827
Drug: 11 mL
Normalized name: camphor 0.11 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 mL of cold anesthetic gel (group 1)
Study: 15253827
Drug: Plain lubricating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain lubricating gel (group 2)
Study: 15253827
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel (group 3)
Study: 9243105
Drug: Fasting immunoreactive
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting immunoreactive insulin
Study: 9243105
Drug: Proinsulin/specific insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proinsulin/specific insulin ratio
Study: 9243105
Drug: Specific insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specific insulin
Study: 9243105
Drug: Proinsulin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proinsulin and proinsulin/specific insulin ratio
Study: 9243105
Drug: High proinsulin/specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: High proinsulin/specific insulin ratio
Study: 8440766
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg nicotine per day
Study: 8440766
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg nicotine per day
Study: 8440766
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg nicotine per day
Study: 8440766
Drug: Nicotine Transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Transdermal System 21 mg/day
Study: 8440766
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of Nicotine Transdermal System 7 mg/day plus 14 mg/day
Study: 29584456
Drug: Avelumab in
Normalized name: avelumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab in combination with pegylated liposomal doxorubicin
Study: 28857740
Drug: Double-blind drug
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind drug reduction programme leading to full withdrawal within 6 months.
Study: 28857740
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control group maintained baseline level of medication).
Study: 11071974
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - Oral conjugated oestrogen (0.625 mg) + medroxyprogesterone acetate (2.5 mg) daily for 12 weeks
Study: 8450327
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous nicardipine
Study: 334808
Drug: Phenytoin 100
Normalized name: phenytoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 100 mg
Study: 29720244
Drug: Taurolidine-citrate lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine-citrate lock solution
Study: 26463420
Drug: Mandibular Advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular Advancement Therapy (MAD)
Study: 23158856
Drug: Hydrocortisone 100
Normalized name: hydrocortisone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 100 mg intravenous, 3 times/day for 7 days
Study: 20627914
Drug: Bronchodilators (salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators (salbutamol plus ipratropium)
Study: 19097963
Drug: Meperidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.4 mg/kg
Study: 16177972
Drug: Echinilin (Echinacea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinilin (Echinacea purpurea) administered at onset of cold for 7 days, 5 mL/dose on day 1 and 3 doses on subsequent days
Study: 16177972
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at onset of cold for 7 days
Study: 12952843
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (10 mg/d) and ARB (candesartan, 8 mg/d) for 3 days (GTN+ARB group)
Study: 12952843
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (10 mg/d) for 3 days (GTN group)
Study: 12952843
Drug: Placebo skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo skin patches and placebo tablets for 3 days (control group)
Study: 12952843
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (10 mg/d) (GTN group)
Study: 12952843
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (10 mg/d) and ARB (candesartan, 8 mg/d) (GTN+ARB group)
Study: 9892314
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day of glycine (N=9)
Study: 10829989
Drug: Malnourished children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malnourished children with hypoalbuminemia (serum albumin < 2.5 g/dl)
Study: 10829989
Drug: Malnourished children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malnourished children with anemia (hemoglobin < or = 8.0 g/dl)
Study: 6625248
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg . kg‐1 and fentanyl 6 micrograms . kg‐1 (Group M)
Study: 6625248
Drug: Thiopentone 6
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 6 mg . kg‐1 and fentanyl 5 micrograms . kg‐1 (Group T)
Study: 29041916
Drug: Coordinated rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordinated rehabilitation programme with early onset of patient participation and intensified occupational therapy and physiotherapy after hip fracture surgery.
Study: 23766611
Drug: Intralesional Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Steroids
Study: 12081605
Drug: Thymosin-alpha1 and
Normalized name: Thymosin alpha1 (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin-alpha1 and famciclovir combination therapy
Study: 12081605
Drug: Famciclovir monotherapy
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famciclovir monotherapy
Study: 2024560
Drug: Droperidol (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.03 mg.kg‐1 to 0.25 mg.kg‐1) with fentanyl
Study: 30764731
Drug: Angiography-based machine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiography-based machine learning (ML) algorithm
Study: 27046461
Drug: levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.25% + tramadol 1 mg/kg
Study: 27046461
Drug: levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.25% + tramadol 2 mg/kg
Study: 26435060
Drug: Glucose consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose consumption (25% of daily energy requirements)
Study: 26435060
Drug: Fructose consumption
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose consumption (25% of daily energy requirements)
Study: 26435060
Drug: High fructose
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fructose corn syrup (HFCS) consumption (25% of daily energy requirements)
Study: 26788345
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil (GEn) 600 mg
Study: 19762734
Drug: 1.0 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL/kg of 0.225% ropivacaine (low volume/high concentration, LVHC)
Study: 15551194
Drug: Olanzapine (OLA)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (OLA) 5-20 mg/d
Study: 15551194
Drug: Flupenthixol (FLU)
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol (FLU) 5-20 mg/d
Study: 10658681
Drug: IL-2 +
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 + G-CSF mobilization
Study: 10658681
Drug: G-CSF mobilization
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF mobilization alone (Control)
Study: 3935466
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (Nitroderm TTS 5)
Study: 29117472
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention (weekly messages for 22 weeks) in addition to healthy lifestyle counselling
Study: 21046932
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of OROS hydromorphone once daily
Study: 21046932
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of immediate-release hydromorphone four times daily
Study: 18561878
Drug: Prophylactic Implantable
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic Implantable Cardioverter Defibrillator (ICD) therapy
Study: 16525182
Drug: Conventional radiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy, intensity-modulated radiotherapy, brachytherapy, radiosurgery, photodynamic therapy
Study: 16525182
Drug: Convection-enhanced delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convection-enhanced delivery of chemotherapy
Study: 16525182
Drug: New experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: New experimental therapies such as immunotherapy
Study: 12411282
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 0.12, 0.9, or 7% saline
Study: 12411282
Drug: Pretreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with amiloride followed by inhalation of 0.12 and 0.9% saline
Study: 12411282
Drug: Pretreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with amiloride and inhalation of 7% saline
Study: 12411282
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of vehicle (0.12% saline)
Study: 11074391
Drug: Topical growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical growth factors (particularly platelet-derived growth factor)
Study: 11074391
Drug: Topical ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketanserin
Study: 11074391
Drug: Systemic hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic hyperbaric oxygen therapy
Study: 8975251
Drug: newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: newly developed film‐coated tablet with sustained release
Study: 8975251
Drug: reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: reference formulation
Study: 1310572
Drug: Foscarnet induction
Normalized name: foscarnet Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet induction therapy at a dosage of 60 mg/kg 3 times/day via 1-hour intravenous infusion for 21 days.
Study: 1310572
Drug: Foscarnet maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet maintenance therapy at a dosage of 90 mg/kg/day via 2-hour infusion.
Study: 1310572
Drug: Foscarnet treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet treatment delayed until the first signs of retinitis progression (Control group).
Study: 7398735
Drug: Microencapsulated digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microencapsulated digoxin capsules (0.38 mg)
Study: 7398735
Drug: Commercial tablets
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial tablets (ultrarapidly dissolving)
Study: 31444589
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg enfortumab vedotin (Arm A)
Study: 31444589
Drug: 1.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/kg enfortumab vedotin (Arm B)
Study: 31444589
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of enfortumab vedotin
Study: 21857489
Drug: Drug conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conservation group (deferred ART)
Study: 18254574
Drug: Prednisolone oral
Normalized name: prednisolone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone oral solution + placebo tablets + procaterol MDI
Study: 18254574
Drug: Prednisolone tablets
Normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone tablets + placebo oral solution + procaterol MDI
Study: 14568892
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg)
Study: 2097565
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg b.i.d. e.v.) starting from the day before the operation and continuing for the following seven days
Study: 2097565
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (5,000 IU b.i.d. by s.c. route) from day 0 to the 7th post-operative day
Study: 31912787
Drug: Frozen gloves
Normalized name: GLOVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen gloves (FGs) worn on both hands during chemotherapy
Study: 2393206
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg four times daily for 2 days
Study: 7032370
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal solution (300 micrograms/day)
Study: 28068956
Drug: Beta-lactam/macrolide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam/macrolide combination
Study: 25788197
Drug: LAM 100
Normalized name: midazolam 100 MG in 100 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM 100 mg daily
Study: 25788197
Drug: ADF 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADF 10 mg daily
Study: 21414565
Drug: aliskiren/amlodipine/HCTZ (300/10/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: aliskiren/amlodipine/HCTZ (300/10/25 mg)
Study: 21414565
Drug: aliskiren/amlodipine (300/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: aliskiren/amlodipine (300/10 mg)
Study: 19153265
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aliskiren and Losartan
Study: 9063541
Drug: Powdered HSA
Normalized name: 125 I HSA
DrugBank: Albumin iodinated I-125 serum (DB09429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered HSA charcoal (2,000 m2/g)
Study: 9063541
Drug: Low-surface-area (LSA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-surface-area (LSA) charcoal (950 m2/g)
Study: 8095006
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion at 3 ng min-1kg-1
Study: 8095006
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion at 6 ng min-1kg-1
Study: 8095006
Drug: Octreotide pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide pretreatment (0.8 microgram/kg subcutaneously) before insulin infusion
Study: 8095006
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during hypoglycaemia
Study: 26757788
Drug: LY3015014 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3015014 300 mg every 4 weeks (Q4W)
Study: 26757788
Drug: LY3015014 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3015014 300 mg every 8 weeks (Q8W)
Study: 12648985
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy with propranolol (with or without isosorbide‐5‐mononitrate [ISMN])
Study: 1582601
Drug: Nicardipine 3
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 3 mg
Study: 23036478
Drug: AG200-15 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 patch (highest dose)
Study: 23036478
Drug: Lowest-dose patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest-dose patch
Study: 23036478
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three patches
Study: 15328674
Drug: Educational handout
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational handout monthly for 2 months
Study: 3109017
Drug: Enprostil, 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil, 35 micrograms twice daily
Study: 1972218
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral nicotinamide daily for three weeks
Study: 1972218
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for three weeks
Study: 31274492
Drug: Phrenic Nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phrenic Nerve Infiltration with 10 mL of 0.2% Ropivacaine
Study: 31274492
Drug: Paracetamol Infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol Infusion with 20mg/kg
Study: 25873635
Drug: Tabalumab 120
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 120 mg every four weeks (120/Q4W)
Study: 25873635
Drug: Tabalumab 90
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 90 mg every two weeks (90/Q2W)
Study: 23567397
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (50-300 mg/day, flexible dosing)
Study: 11543984
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Delta(9)-tetrahydrocannabinol (THC) with ethanol (0.35 g/kg)
Study: 11543984
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose Delta(9)-tetrahydrocannabinol (THC) with ethanol (0.7 g/kg)
Study: 9631978
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination of bisoprolol/hydrochlorothiazide
Study: 8161715
Drug: Dilapress 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilapress 120 mg tablets (twice-daily dosing)
Study: 8161715
Drug: Dilapress 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilapress 240 mg tablets (once-daily treatment)